Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Relapsed Acute Myeloid Leukemia

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Acute Myelocytic Leukemia (AML,...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Human Epidermal Growth Factor...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Recurrent Head And Neck...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Nasopharyngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Nasopharyngeal Cancer

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Laryngeal Cancer: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Laryngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Laryngeal Cancer

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Hypopharyngeal Cancer: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Hypopharyngeal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Hypopharyngeal Cancer

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Soft Tissue Sarcoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Soft Tissue Sarcoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Soft Tissue Sarcoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Hepatocellular Carcinoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Hepatocellular Carcinoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Refractory Acute Myeloid Leukemia

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for B-Cell Acute Lymphocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Marginal Zone B-cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Marginal Zone B-cell Lymphoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Follicular Lymphoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Follicular Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Follicular Lymphoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Burkitt Lymphoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Burkitt Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Burkitt Lymphoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Mantle Cell Lymphoma: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Mantle Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Mantle Cell Lymphoma

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Sezary Syndrome: Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Sezary Syndrome. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Sezary Syndrome

Data Insights

Mitoxantrone hydrochloride by CSPC Pharmaceutical Group for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Mitoxantrone hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Human Epidermal Growth Factor...

Likelihood of Approval and Phase Transition Success Rate Model - Mitoxantrone Hydrochloride in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)